Cardiff Oncology's Onvansertib Shows Promise in First-Line mCRC Trial
Event summary
- Cardiff Oncology’s Phase 2 trial (CRDF-004) showed dose-dependent improvements in overall response rates and progression-free survival (PFS) when onvansertib was added to FOLFIRI/bevacizumab in first-line RAS-mutated mCRC.
- The 30mg dose of onvansertib combined with FOLFIRI/bevacizumab demonstrated the most favorable results, with a PFS HR of 0.37 (vs SoC) and an ORR of 72.2%.
- The company plans to initiate a registrational program later in 2026, comparing onvansertib with FOLFIRI/bevacizumab to standard-of-care regimens.
- Data suggest onvansertib was well-tolerated, with no major or unexpected toxicities observed.
The big picture
The Phase 2 data represent a significant advancement in the treatment of RAS-mutated mCRC, a patient population with limited therapeutic options. Onvansertib’s novel mechanism of action as a PLK1 inhibitor addresses a critical unmet need in oncology, potentially shifting the standard of care for this patient segment. The company's decision to move directly to a registrational trial underscores the perceived strength of the data and the potential for a rapid market entry.
What we're watching
- Regulatory Approval
- The success of the planned registrational trial will be critical for securing FDA approval and establishing onvansertib as a new standard of care, which hinges on the FDA’s consultation and acceptance of the trial design.
- Competitive Landscape
- The emergence of onvansertib as a potential first-line treatment could intensify competition within the mCRC market, potentially impacting the market share of existing therapies.
- Commercialization
- Cardiff Oncology's ability to successfully commercialize onvansertib, including securing reimbursement and establishing a robust sales infrastructure, will be key to realizing the drug’s full potential.
Related topics